January 19, 2020
3 min read
Save

Diabetes and the heart: Top news of 2019

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio and Cardiology Today compiled a list of the most-read articles on updates in diabetes and CVD published in 2019.

This year, Healio readers were most interested in the changing role of cardiologists in diabetes care and new data from trials including DAPA-HF, THEMIS, REWIND and more. See below for the top articles, in no particular order.

 

Cardiologists’ role in diabetes care changing

The Cardiology Today June 2019 cover story focused on the increased involvement of cardiologists in the care of patients with type 2 diabetes, in light of an avalanche of data that continue to demonstrate CV benefits of diabetes drugs including SGLT2 inhibitors and GLP-1 receptor agonists. Read more

 

DAPA-HF: Dapagliflozin offers new approach to treatment of HFrEF, even without diabetes

In patients with HF, with and without diabetes, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening HF and CV death when added to standard therapy, according to anticipated results of the DAPA-HF trial presented at the European Society of Cardiology Congress. Read more

 

THEMIS: Ticagrelor-aspirin DAPT may benefit selected patients with diabetes, stable CAD

Ticagrelor added to low-dose aspirin reduced the incidence of ischemic events in patients with stable CAD and diabetes without a history of MI or stroke, but increased major bleeding compared with aspirin alone, according to results of the THEMIS trial presented at the European Society of Cardiology Congress. Read more

 

DECLARE-TIMI 58 trial validates CV benefits of SGLT2 inhibitors in type 2 diabetes

In a Guest Commentary written by Eldrin Foster Lewis, MD, MPH, with Harvard Medical School and Brigham and Women’s Hospital, he discusses the clinical implications of the DECLARE-TIMI 58 trial and the role of SGLT2 inhibitors in diabetes and CVD. Read more

 

Maintained weight loss improves cardiometabolic risk factors in diabetes

Among patients with diabetes who lost weight, those who maintained their weight loss significantly improved their cardiometabolic risk factors compared with those who regained weight, according to a study published in the Journal of the American Heart Association. Read more

 

Smartphone heart rate tech, deep learning may aid in diabetes detection

A smartphone application that tracks a person’s heart rate may be able to detect diabetes using a photoplethysmography signal, which is easily measured using a smartphone’s light and camera, according to a study presented at the American College of Cardiology Scientific Session. Read more

PAGE BREAK

 

New insights on diabetes, CVD research from the TIMI Study Group

In a presentation at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in December 2019, speakers highlighted recent data from the TIMI Study Group on treatment options for diabetes and CVD. Read more

 

REWIND: Assessing the role of dulaglutide for primary prevention of CVD

In this Commentary, Bolanle Akinyele, MD, Roger S. Blumenthal, MD, and Sudipa Sarkar, MD, MSCI, discuss results of the REWIND trial, presented at the American Diabetes Association Scientific Sessions in June 2019. Read more

 

Age at type 2 diabetes diagnosis may impact survival, CVD outcomes

The age at diagnosis of type 2 diabetes in patients may be important for determining survival and CV outcomes, according to findings published in Circulation. Read more

 

CAROLINA: Active-comparator study ‘vindicates’ glimepiride for CV safety

A head-to-head comparison of the sulfonylurea glimepiride against the DPP-IV inhibitor linagliptin in a cohort of more than 6,000 adults with type 2 diabetes demonstrated no between-group differences for incidence of nonfatal MI, nonfatal stroke and CV death during a median of 6 years, according to data presented at the American Diabetes Association Scientific Sessions. Read more

 

FDA approves canagliflozin to treat diabetic kidney disease, HF hospitalization

In September, the FDA approved a new indication for the SGLT2 inhibitor canagliflozin to reduce the risk for end-stage renal disease, worsening of kidney function, CV death and hospitalization for HF among adults with type 2 diabetes and diabetic kidney disease. Read more

 

FDA expands dapagliflozin indication to reduce HF hospitalization

The diabetes drug dapagliflozin has been approved by the FDA to reduce the risk for HF hospitalization among adults with type 2 diabetes who also have CVD or multiple CV risk factors, according to a press release from AstraZeneca. Read more